Loading clinical trials...
Loading clinical trials...
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3
Conditions
Interventions
adeno-associated virus vector AAV- CNGA3
Locations
2
United States
Kellogg Eye Center
Ann Arbor, Michigan, United States
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Start Date
August 12, 2019
Primary Completion Date
June 10, 2021
Completion Date
June 10, 2021
Last Updated
December 1, 2022
Lead Sponsor
MeiraGTx UK II Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions